Patient Guide
Clinical Trials and Research Participation
Phases, informed consent, your rights, and relation to standard care
Clinical trials systematically test new drugs, combinations, devices, or approaches. Participation is voluntary; declining should not block standard care. Ethics review and informed consent are mandatory.
“Last resort” is not always the right frame — some trials exist in earlier settings. Clarify the standard alternative, arms, extra visits, and toxicity monitoring in writing.
When are trials discussed?
When standard options are limited, a biologic subtype is targetable, or new combinations are being studied, your team may screen for suitable trials. Not every patient fits every study — inclusion and exclusion criteria are strict.
- Stage and prior therapies
- Biomarker / molecular fit
- Organ function and performance status
- Travel / visit burden
Phases in brief
Phase I focuses on safety and dose; Phase II on efficacy signals; Phase III on comparison with standard care. Earlier phases carry more unknowns. Phase number alone is not a quality guarantee — read the protocol summary.
Your rights
Read consent forms without rush; ask about anything unclear. You may withdraw anytime without needing to justify. Withdrawal should not close standard-care access. Data handling follows protocol and privacy rules.
- Voluntary participation
- Withdrawal anytime
- Standard care access should remain
- Write your questions down
Questions to ask
What is the standard alternative? Is there a placebo or blinding? How often are extra scans / blood tests? Who monitors toxicity around the clock? Is travel support available? How will results be shared with you?
Realistic expectations
A trial is not a promise of miracle cure. Some arms may match or beat standard care; some may not. Benefit–risk is discussed against the protocol, your stage, and your values.
Common questions
- Are trials only a last resort?Tap for details
Sometimes, but appropriate trials also exist in earlier settings. The label does not fit every protocol.
- If I decline, will care worsen?Tap for details
No. Declining should not affect access to standard treatment.
- If there is a placebo arm, will I get no drug?Tap for details
Oncology designs vary; many add to standard care or use active comparators. Clarify in the consent form.
- Who pays?Tap for details
Research-related extras are often covered by the sponsor / site; routine care items may differ — ask in writing.
Evidence
Scientific sources
Show sources · 1Ethics and patient-rights framing for clinical trial participation and informed consent.
Evidence
Scientific sources
- 1. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upEuropean Society for Medical Oncology (ESMO) · 2023 · DOI: 10.1016/j.annonc.2022.10.003Open source →
Last reviewed: 21 August 2026. Links go to publisher pages.
Bu rehber bilgilendirme amaçlıdır; tıbbi tavsiye, teşhis veya tedavi yerine geçmez. Ameliyatınıza özel yazılı talimatlar önceliklidir. Acil bulgularda gecikmeden sağlık kuruluşuna başvurun.